Eagle Pharmaceuticals (EGRX) Reports In-Line Q1 EPS

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.42, in-line with the analyst estimate of $1.42. Revenue for the quarter came in at $76.8 million versus the consensus estimate of $70.37 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance